SAN MATEO, Calif., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the appointment of Barbara Kosacz as Chief Operating Officer and General Counsel. Ms. Kosacz joins the Company with more than 25 years of experience providing strategic and legal advice to life sciences companies, and served most recently as international head of Cooley LLP’s Life Sciences Practice. In her role at Kronos, she will be responsible for internal operations and legal functions within the Company.
“Barbara is universally recognized as one of the top life sciences attorneys in the country, having worked with clients in structuring and negotiating some of the most transformational transactions in our industry. She brings a wealth of business and legal experience covering the full spectrum of issues healthcare companies face,” said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. “As a member of the Executive Leadership Team, Barbara will be integrally involved in determining and delivering on our corporate strategy as we transition to clinical-stage, following our recent acquisition of the spleen tyrosine kinase inhibitor portfolio from Gilead, and advancement of our pipeline of oncology drug candidates.”
During her long tenure with Cooley, a leading international law firm with deep roots in the Life Sciences industry, Ms. Kosacz worked with clients ranging from early-stage start-ups to large public companies, helping them set strategic direction and negotiate mission-critical transactions. Along the way, she racked up an array of awards and accomplishments, including being listed as Biotechnology Lawyer of the Year for 2018 by Best Lawyers in America, listed as a “Band 1” attorney by Chambers USA: America's Leading Lawyers for Business, and being elected to “Super Lawyers” annually since 2011. She has been recognized as a “highly recommended transactions” lawyer by IAM Patent 1000 for “advising diverse companies in the industry at a deeply strategic and commercial level and overseeing their most complex and profitable deals.” Barbara is a thought leader in the industry and has the distinction of having served as a member of the BIO Emerging Companies' Section Governing Board, and as guest lecturer at Berkeley Law and Stanford Law School. Ms. Kosacz also served multiple terms on Cooley’s management committee, overseeing the firm during its greatest growth periods.
“Having spent the majority of my career as an external advisor to biopharma companies, I’m thrilled to be joining Kronos and playing a deeper, more operational role,” said Ms. Kosacz. “While my decision to leave private practice was a tough one, my decision to join Kronos was easy, given the Company’s top-notch leadership team, robust pipeline, deep expertise in computational biology, proprietary product engine designed to address well-known yet historically “undruggable” targets, and strong financial position. I look forward to working closely with this accomplished team to help achieve our long-term goal of transforming outcomes for cancer patients.”
Ms. Kosacz is a member of the Board of Directors of XOMA Corporation and is on the Board of Trustees of the Keck Graduate Institute. She earned a B.A. from Stanford University and a J.D. from the University of California, Berkeley, School of Law.
About Kronos Bio
Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.